Braf protein mutation and its significancy within patients with melanoma
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.076Keywords
braf kinase, braf mutation, melanoma, wemurafenibAbstract
Introduction and purpose:
This review aims to analyze BRAF mutation significancy and its influence on progression and therapy methods within patients with melanoma.
Material and method:
This review was mainly based on articles collected in Pubmed in years 2004-2018. The research was done by looking through keywords as follows “braf kinase”, “braf mutation”, “melanoma” “wemurafenib”.
Results:
The selected studies have demonstrated that it is justified to identify patient with BRAF mutation due to it’s influence on treatment’s method choosing.
Conclusions:
Citied researches have proven BRAF mutation significancy in growth and progressions of many malignant tumors. Further tests are likely to not only prolong life expectancy within patients with melanoma, but also being a source of crucial knowledge about tumors development.
References
Zaleśna I, Hartman ML, Czyż M. Znaczenie mutacji BRAF dla progresji i terapii czerniaka, raka brodawkowatego tarczycy i raka jelita grubego [BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma]. Postepy Hig Med Dosw (Online). 2016 May 9;70:471-88. Polish. doi: 10.5604/17322693.1201719. PMID: 27180965.
Cope N, Candelora C, Wong K, Kumar S, Nan H, Grasso M, Novak B, Li Y, Marmorstein R, Wang Z. Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein. Chembiochem. 2018 Sep 17;19(18):1988-1997. doi: 10.1002/cbic.201800359. Epub 2018 Aug 17. PMID: 29992710; PMCID: PMC6504641.
Paweł M. Potocki, Piotr J. Wysocki. BRAF — nowy cel terapeutyczny w raku jelita grubego [BRAF — a new therapeutic target in colorectal cancer]. Varia Medica 2018 tom 2, nr 3, strony 247–257 Copyright © 2018 Via Medica ISSN 2544-4212 Oncol Clin Pract 2018; 14; DOI: 10.5603/OCP.2018.0013 Polish
Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R., Cancer Genome Project: Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004; 116: 855-867
Piotr Rutkowski, Piotr J. Wysocki Cutaneous melanomas Oncol Clin Pract 2017;13(6):241-258 DOI: 10.5603/OCP.2017.0038 Polish
Krajowy Rejestr Nowotworów http://onkologia.org.pl/czerniak-skory-2/
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. PMID: 22554099; PMCID: PMC3391993.
Sorafenib (opis profesjonalny) https://www.mp.pl/pacjent/leki/subst.html?id=4577
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Julia Kuchnicka, Aleksandra Kuchnicka, Katarzyna Kosz, Klaudia Remjasz, Natalia Zarankiewicz, Martyna Zielińska, Klaudia Sapuła, Jakub Aleksandrowicz, Wojciech Siedlecki
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 303
Number of citations: 0